Session » (1308–1344) RA – Treatments Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1318

Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial

9:00AM-11:00AM: Abstract Number: 1336

Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering

9:00AM-11:00AM: Abstract Number: 1343

Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years

9:00AM-11:00AM: Abstract Number: 1308

Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study

9:00AM-11:00AM: Abstract Number: 1330

Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

9:00AM-11:00AM: Abstract Number: 1334

Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

9:00AM-11:00AM: Abstract Number: 1310

Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice

9:00AM-11:00AM: Abstract Number: 1317

Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1323

Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1

9:00AM-11:00AM: Abstract Number: 1321

Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1337

Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1335

Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)

9:00AM-11:00AM: Abstract Number: 1327

Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials

9:00AM-11:00AM: Abstract Number: 1344

Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1322

Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

9:00AM-11:00AM: Abstract Number: 1315

Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies

9:00AM-11:00AM: Abstract Number: 1320

Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 1341

Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores

9:00AM-11:00AM: Abstract Number: 1316

Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1325

Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years

9:00AM-11:00AM: Abstract Number: 1331

Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

9:00AM-11:00AM: Abstract Number: 1339

Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1332

Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)

9:00AM-11:00AM: Abstract Number: 1324

Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

9:00AM-11:00AM: Abstract Number: 1329

R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1319

Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients

9:00AM-11:00AM: Abstract Number: 1340

Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data

9:00AM-11:00AM: Abstract Number: 1309

Refractory RA Patients for Targeted Therapies in Real Life

9:00AM-11:00AM: Abstract Number: 1313

Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1333

Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset

9:00AM-11:00AM: Abstract Number: 1326

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study

9:00AM-11:00AM: Abstract Number: 1314

Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA

9:00AM-11:00AM: Abstract Number: 1328

Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation

9:00AM-11:00AM: Abstract Number: 1311

T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1338

The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort

9:00AM-11:00AM: Abstract Number: 1342

The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1312

Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].